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Background: Intramuscular interferon beta-1a (IFNβ-1a), a multiple sclerosis (MS) therapy that 
has been commercially available for over a decade, provides a unique opportunity to retrospec-
tively assess postmarketing data for evidence of malignancy risk, compared with relatively limited 
data available for more recently approved therapies. Postmarketing and claims data were analyzed 
to determine the risk of malignancy in MS patients treated with intramuscular IFNβ-1a.
Materials and methods: The cumulative reporting rates of suspected adverse drug reactions 
coded to malignancy in the intramuscular IFNβ-1a global safety database were compared with 
malignancy incidence rates in the World Health Organization GLOBOCAN database. In addition, 
using data from a large US claims database, the cumulative prevalence of malignancy in MS 
patients treated with intramuscular IFNβ-1a was compared with non-MS population controls, 
MS patients without intramuscular IFNβ-1a use, and untreated MS patients. Mean follow-up was 
approximately 3 years for all groups, ie, 3.1 years for the intramuscular IFNβ-1a group (range 
0.02–6.0 years), 2.6 years for non-MS population controls (range 0–6.0 years), 2.6 years for 
the intramuscular IFNβ-1a nonuse group (range 0.01–6.0 years), and 2.4 years for the untreated 
MS group (range 0.01–6.0 years).
Results: An estimated 402,250 patients received intramuscular IFNβ-1a during the postmarket-
ing period. Cumulative reporting rates of malignancy in this population were consistent with 
GLOBOCAN incidence rates observed within the general population. The claims database included 
12,894 MS patients who received intramuscular IFNβ-1a. No significant difference in malig-
nancy prevalence was observed in intramuscular IFNβ-1a users compared with other groups.
Conclusion: Results from this evaluation provide no evidence of an increased risk of malignancy 
with intramuscular IFNβ-1a use.
Keywords: multiple sclerosis, malignancy, safety, intramuscular interferon beta-1a, postmar-
keting surveillance, claims
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system. Although there is no cure for MS, treatment with disease-modifying therapies 
can improve the clinical course by reducing the frequency of relapses and, with some 
treatments, slow the accumulation of physical disability commonly associated with MS. 
Because patients are typically diagnosed between 20 and 40 years of age1 and MS is a 
lifelong disease, MS patients may use immunomodulatory disease-modifying therapies 
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for extended periods of time, which may affect some aspects 
of immunosurveillance.2 Given that some malignancies could 
be affected by use of these immunomodulatory therapies, it is 
important to evaluate the effect of various disease-modifying 
therapies on malignancy risk beyond short-duration clinical 
trials.
The pathogenesis of MS is believed to involve an 
inappropriate immune response mediated by autoreactive 
lymphocytes within the central nervous system.1 While the 
association between autoimmune disease and cancer is not 
fully understood, autoreactive T cells have been shown to 
influence both the prevention and the advancement of cancer.3 
The heightened immune system activity in MS may prevent 
the development of cancer, leading to a reduction in cancer 
risk in the MS population.4 Any modification of the immune 
system, in particular one involving activation of T cells, 
therefore carries the potential of changing the occurrence of 
cancer. Lifestyle changes following a diagnosis of MS may 
also contribute to a lowered cancer risk.5 Multiple studies 
have examined the relationship between MS and cancer 
risk,5–12 and while a lower overall risk of developing cancer 
in patients with MS has been observed in some studies,5,6,9,13 
the majority of these analyses have concluded that there 
is no difference in the risk of developing malignancies 
between patients with MS and the general population.7,8,10–12 
In addition, a few studies have suggested an increased risk 
of developing site-specific cancers, such as breast cancer,11 
urinary cancer,5 and brain cancer.5
Recent studies have also examined the risk of malignancy 
in MS patients who have been exposed to disease-modifying 
therapies.4,14–16 The disease-modifying therapies evaluated 
in these studies (glatiramer acetate, interferon beta-1a 
[IFNβ-1a], and IFNβ-1b) have been commercially available 
for over 10 years. Results have suggested that there is no dif-
ference in risk for MS patients treated with disease-modifying 
therapies compared with the general population. However, 
a decreased risk of development of several types of cancer 
in patients treated with these therapies was observed in one 
study,14 while another investigation found a nonsignificant 
trend of elevated risk of nonbreast cancers.4
Intramuscular IFNβ-1a (Avonex®; Biogen Idec, Weston, 
MA) is a first-line disease-modifying therapy administered 
weekly for treatment of relapsing forms of MS. Intramuscular 
IFNβ-1a was first approved for use in MS by the United States 
Food and Drug Administration in May 1996 and is currently 
approved for use in 89 countries. Safety information available 
from the pivotal clinical trials at the time of product approval 
did not suggest an increased risk of malignancy.17,18
A global safety database was utilized to capture all 
intramuscular IFNβ-1a safety data during the postmarketing 
period. Currently, 15 years of postapproval data are available 
to evaluate the risk of malignancy. Insurance claims data 
from health plans, which include information on patient 
demographics, diagnoses, medical procedures, laboratory 
testing, and pharmacy data, offer an additional opportunity 
to evaluate the risk of malignancy related to use of disease-
modifying therapies.
In this evaluation, we aimed to assess the malignancy risk 
associated with intramuscular IFNβ-1a treatment in patients 
with MS using postmarketing surveillance data from a global 
product safety database along with data from a large US 
claims database. This paper provides postmarketing safety 
data for intramuscular IFNβ-1a-treated patients that have not 
previously been published.
Materials and methods
Descriptions of the two data sources and the corresponding 
analyses used in this evaluation are provided below.
Intramuscular IFNβ-1a global  
safety database
The intramuscular IFNβ-1a global safety database captures 
all suspected adverse drug reactions with intramuscular 
IFNβ-1a reported to Biogen Idec worldwide since product 
approval, including spontaneous reports, literature case 
reports, and serious suspected adverse drug reactions from 
the intramuscular IFNβ-1a clinical trials. Suspected adverse 
drug reactions are coded using Medical Dictionary for 
Regulatory Activities (MedDRA)19 terminology. Any event 
confirmed by a health care provider is considered a suspected 
adverse drug reaction unless a causality assessment of “not 
related” is provided by the treating health care provider. In 
addition, a large number of potential adverse drug reactions 
are captured in the intramuscular IFNβ-1a global safety 
database during contact with patients through an intramus-
cular IFNβ-1a toll-free support phone line, a patient support 
service provided by Biogen Idec, and through other formal 
postmarketing initiatives, such as nurse training programs 
and home drug delivery.
A cumulative review was performed of all suspected 
adverse drug reactions coded to a malignancy using MedDRA 
coding from May 1996 through April 2011. Adverse drug 
reactions coded to the terms “cancer,” “neoplasm,” or 
“malignancy” were queried and evaluated. Benign neoplasms 
were removed from this analysis; only cases with terms coded 
to a malignancy were included. Person-years of exposure 
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were calculated based on monthly sales data from each 
country based on the assumption that 52 vials or syringes of 
intramuscular IFNβ-1a are equivalent to one person-year of 
exposure (ie, each vial or syringe is equivalent to a weekly 
dose of intramuscular IFNβ-1a).
The cumulative reporting rates of malignancies by 
primary site in the intramuscular IFNβ-1a global safety 
database were compared with the most recently reported 
age-standardized incidence rates for malignancies in the 
GLOBOCAN 2008 database.20 GLOBOCAN, a project of 
the World Health Organization’s International Agency for 
Research on Cancer, is a worldwide epidemiological cancer 
database that provides country-by-country estimates of the 
incidence of and mortality from major type of cancers within 
the general population.20 Population-weighted averages of 
the national incidence rates (derived from population-based 
cancer registries) from the 2008 GLOBOCAN database for 
“more developed regions” (North America, Europe, Japan, 
Australia, and New Zealand) were used for comparison, 
because approximately 85% of the marketed product is 
distributed within these regions (Biogen Idec, data on file).
Insurance claims database
The second data source used in this evaluation was the 
i3 InVision™ Data Mart Multiplan (PharmaNet/i3, Princeton, 
New Jersey), a large US health insurance claims database 
covering approximately 77,000,000 lives from 48 plans across 
seven regions of the country. Claims data from July 2004 
through June 2010 were   analyzed, with diagnosis terms coded 
to International   Classification of Disease (ICD-9) criteria. 
In order to minimize exposure misclassification, only sub-
jects with pharmacy benefits were included in the analysis.
The objective of this analysis was to determine the 
cumulative prevalence of malignancy in MS patients using 
intramuscular IFNβ-1a and to make comparisons with 
non-MS population controls, intramuscular IFNβ-1a non-
use MS patients, and untreated MS patients. MS cases were 
limited to patients with at least two diagnosis codes for MS 
(ICD-9 340). Cases with at least one intramuscular IFNβ-1a 
prescription after the index MS diagnosis date (the date of the 
first diagnosis of MS in the database) were designated intra-
muscular IFNβ-1a use; those with an indicated MS treatment 
and/or immunosuppressive treatment but no intramuscular 
IFNβ-1a prescriptions at any time were designated intramus-
cular IFNβ-1a nonuse. Cases with no use of an indicated 
MS treatment and no immunosuppressive treatment were 
designated untreated MS. Immunosuppressive drugs included 
those that were most likely to be used by patients with MS 
(mitoxantrone, rituximab, cyclophosphamide, azathioprine, 
methotrexate, mycophenolate, and cladribine).
For each MS case, two population controls with no   history 
of MS were selected from the database, matched on age, gender, 
and follow-up time. Each control was assigned the index date 
of the matched case for the purpose of longitudinal analyses. 
Follow-up time was calculated as the time in the database from 
the index MS diagnosis date for cases and their controls. Mean 
follow-up time was approximately 3 years for all groups.
The outcome was defined as more than one diagnosis code 
for malignancy in any position of the claim at least 30 days 
apart. More than one diagnosis code was required in order 
to increase the confidence that true malignancy cases were 
being captured. Table 1 provides the malignancy exclusion 
criteria applicable to each group.
To provide a measure of the magnitude of the differences, 
the prevalence odds ratio was calculated as the prevalence of 
malignancy in the intramuscular IFNβ-1a use group divided 
by the prevalence of malignancy in the comparison group. 
To indicate the strength of the association between preva-
lence estimates, 95% confidence intervals were calculated. 
Table  1  Group  definitions  and  malignancy  exclusion  criteria, 
i3 InVision Data Mart Multiplan analysis
Group  
name
Group  
definition
Malignancy  
exclusion criteria
IM IFNβ-1a  
use
Subjects with at least  
two ICD-9 codes for  
MS and at least one IM  
IFNβ-1a prescription  
after the index MS  
diagnosis datea
Subjects were not  
counted as a case of  
malignancy if there were  
at least two ICD-9 codes  
for the malignancy prior  
to the first IM IFNβ-1a  
prescription date
IM IFNβ-1a  
nonuse
Subjects with at least  
two ICD-9 codes for  
MS and no IM IFNβ-1a  
prescriptions at any  
time in the database
Subjects were not counted   
as a case of malignancy  
if there were at least  
two ICD-9 codes for the  
malignancy prior to the  
index MS diagnosis datea
Untreated  
MS
Subjects with at least two  
ICD-9 codes for MS who  
had no use of an indicated  
MS treatment and no  
immunosuppressive  
treatment at any time  
in the database
Subjects were not counted   
as a case of malignancy  
if there were at least  
two ICD-9 codes for the  
malignancy prior to the  
index MS diagnosis datea
Non-MS  
population  
control
Subjects with no history  
of MS anytime in the  
database
At least two ICD-9 codes  
for the malignancy prior  
to the index MS diagnosis  
datea of the matched case
Note: aDate of the first diagnosis of MS seen in the database.
Abbreviations:  ICD-9,  International  Classification  of  Disease;  IM  IFNβ-1a, 
intramuscular interferon beta-1a; MS, multiple sclerosis.
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All tests assumed a two-sided alternative hypothesis and a 
0.05 significance level. A Bonferroni correction to adjust for 
multiple comparisons resulted in α , 0.002. All analyses 
were conducted using SAS/STAT® software, version 9.2.
Non-MS population controls were already age-matched by 
definition; when a subset of the population was analyzed (case 
versus case), MS groups were frequency-matched based on 
age to ensure that age distributions between the MS case 
comparisons were similar. Malignancies were grouped based 
on the cancer site categories used in GLOBOCAN 2008.
Results
Intramuscular IFNβ-1a global safety 
database
From May 1996 to April 2011, it was estimated that approxi-
mately 402,250 patients received intramuscular IFNβ-1a treat-
ment with the marketed product, including 261,000 patients 
from the US and 141,250 patients from other countries in 
which intramuscular IFNβ-1a is approved, corresponding to 
approximately 1,492,407 person-years of exposure. For cal-
culating rates of breast, ovarian, cervical, vaginal, and uterine 
carcinomas, the estimated female exposure to intramuscular 
IFNβ-1a was 81% of 1,492,407 person-years (1,208,849 
woman-years) (Biogen Idec, data on file). For calculating 
rates of prostate and testicular carcinomas, the estimated expo-
sure was 283,558 man-years (Biogen Idec, data on file).
The cumulative reporting rates by type of malignancy 
for all suspected reactions within the intramuscular IFNβ-1a 
global safety database were consistent with the incidence 
rates for malignancies in the GLOBOCAN database 
(Table 2). Based on the case reports that included case detail, 
the histological type, stage, and course of malignancies did 
not appear unusual for the patients’ age, gender, and known 
risk factors.
Table 2 Comparison of cumulative reporting rates for suspected reactions coded to malignancies by primary site in the intramuscular 
IFNβ-1a global safety database with GLOBOCAN 2008 incidence rates for more developed regionsa
Primary site of malignancy Cumulative reporting rate  
of suspected reactions  
(per 100,000 person-years), 95% CI
GLOBOCAN 2008 incidence rates  
(age-standardized) for malignancies in more developed 
regionsa (per 100,000 person-years)
Female Male
Bladder 0.74 (0.4–1.3) 3.6 16.3
Brain, nervous system 1.34 (0.8–2.0) 4.4 5.8
Colorectal 3.35 (2.5–4.4) 24.3 37.7
Esophageal 0.34 (0.1–0.7) 1.3 6.5
Hodgkin lymphoma 0.47 (0.2–0.9) 1.9 2.2
Kidney 1.14 (0.7–1.8) 5.9 11.9
Laryngeal 0.00 0.6 5.4
Leukemia 2.14 (1.5–3.0) 5.9 9.1
Liver 0.54 (0.3–1.0) 2.7 8.2
Lung 3.02 (2.2–4.0) 18.8 47.1
Melanoma of skinb 1.88 (1.3–2.7) 8.7 9.6
Multiple myeloma 0.20 (0.05–0.6) 2.2 3.3
Nasopharyngeal 0.07 (0.003–0.3) 0.2 0.6
Non-Hodgkin lymphoma 1.54 (1.0–2.3) 7.1 10.3
Other pharyngeal 0.40 (0.2–0.8) 0.8 4.5
Oral cavity 0.47 (0.2–0.9) 2.3 6.8
Pancreas 0.60 (0.3–1.1) 5.5 8.3
Stomach 0.20 (0.05–0.6) 7.3 16.7
Thyroid 1.74 (1.2–2.5) 9.2 2.9
Breast (females)b 13.9 (11.9–16.1) 66.4 n/a
Cervix (females)b 0.83 (0.4–1.5) 9.1 n/a
Ovary (females) 0.91 (0.5–1.6) 9.3 n/a
Uterine (females) 1.08 (0.6–1.8) 13.0 n/a
Prostate (males) 4.58 (2.5–7.6) n/a 61.7
Testicular (males) 0.35 (0.02–1.7) n/a 4.6
All sites but nonmelanoma skinc 37.05 (34.1–40.2) 226.3 299.2
Notes: aMore developed regions defined as North America, Europe, Japan, Australia, and New Zealand; bdoes not include noninvasive cancers (breast cancer in situ, cervical 
cancer stage 0, and melanoma stage 0), which did not fall into a GLOBOCAN category; cdoes not include basal cell cancer (17), squamous cell cancer (10), skin cancer (1), 
and skin cancer metastatic (1), which did not fall into a GLOBOCAN category.
Abbreviations: CI, confidence interval; IM IFNβ-1a, intramuscular interferon beta-1a; n/a, not applicable.
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Insurance claims database
From July 2004 through June 2010, a total of 95,420 MS cases 
were identified in the claims database. Of these, 12,894 were 
classified as intramuscular IFNβ-1a users. The average age 
of subjects in this analysis was 46 years for all groups: 44.5 
years for the intramuscular IFNβ-1a group (range 5.0–80.0 
years), 44.5 years for non-MS population controls (range 
5.0–80.0 years), 44.9 years for the intramuscular IFNβ-1a 
nonuse group (range 1.0–82.0 years), and 45.4 years for the 
untreated MS group (range 1.0–82.0 years). Seventy-seven 
percent of subjects were female. Mean follow-up time in the 
database was approximately 3 years for all groups: 3.1 years 
for the intramuscular IFNβ-1a group (range 0.02–6.0 years), 
2.6 years for non-MS population controls (range 0–6.0 years), 
2.6 years for the intramuscular IFNβ-1a nonuse group (range 
0.01–6.0 years), and 2.4 years for the untreated MS group (range 
0.01–6.0 years). The mean duration of treatment for the intra-
muscular IFNβ-1a group was 3.0 years (range 0.0–6.0 years).
When malignancy prevalence in the intramuscular 
IFNβ-1a use group was compared with that in non-MS 
population controls, no significant increase in the prevalence 
of malignancy in the intramuscular IFNβ-1a use group was 
observed (Table 3). Similarly, when the malignancy preva-
lence in the intramuscular IFNβ-1a use group was compared 
with the prevalence in MS patients with no use of intramus-
cular IFNβ-1a and in untreated MS patients, no significant 
increase was observed (Tables 4 and 5, respectively).
Discussion
Results from the evaluation of two data sources are consistent 
and provide no evidence of an increased risk of malignancy 
associated with intramuscular IFNβ-1a use. The reported 
rates of malignancies within the intramuscular IFNβ-1a 
global safety database were similar to the reported incidence 
rates in GLOBOCAN for the general population. The fre-
quency and types of malignancies reported were similar to 
those observed within the general population. Cases were 
also reviewed to evaluate malignancies commonly associ-
ated with immunosuppression, such as high-grade lymphoid 
malignancies, Kaposi sarcoma, multiple nonmelanoma skin 
Table 3 Malignancy in MS patients after IM IFNβ-1a use (n = 12,894) compared with non-MS population controls (n = 25,786), 
i3 InVision Data Mart Multiplan
Primary site of  
malignancy
IM IFNβ-1a use Non-MS population controls P valuea Odds ratio  
(95% CI) Malignancy (n) Population (n) % Malignancy (n) Population (n) %
Bladder 11 12892 0.09 16 25782 0.06 0.422 1.38 (0.64–2.96)
Brain 8 12892 0.06 13 25779 0.05 0.647 1.23 (0.51–2.97)
Colorectal 24 12888 0.19 29 25765 0.11 0.071 1.66 (0.96–2.84)
Esophageal 1 12894 0.01 4 25785 0.02 0.509 0.50 (0.06–4.47)
Hodgkin lymphoma 5 12890 0.04 11 25779 0.04 0.859 0.91 (0.32–2.62)
Kidney 8 12890 0.06 14 25778 0.05 0.765 1.14 (0.48–2.72)
Laryngeal 1 12893 0.01 4 25785 0.02 0.509 0.50 (0.06–4.47)
Leukemia 6 12890 0.05 10 25780 0.04 0.726 1.20 (0.44–3.30)
Lip/oral cavity 3 12892 0.02 8 25786 0.03 0.665 0.75 (0.20–2.83)
Liver 3 12894 0.02 6 25784 0.02 1.000 1.00 (0.25–4.00)
Lung 17 12892 0.13 44 25767 0.17 0.356 0.77 (0.44–1.35)
Melanoma 18 12883 0.14 31 25770 0.12 0.616 1.16 (0.65–2.08)
Multiple myeloma 3 12892 0.02 3 25783 0.01 0.401 2.00 (0.40–9.91)
Non-Hodgkin lymphoma 14 12890 0.11 30 25761 0.12 0.829 0.93 (0.49–1.76)
Pancreas 4 12893 0.03 4 25775 0.02 0.332 2.00 (0.50–8.00)
Pharyngeal/ 
nasopharyngeal
2 12893 0.02 4 25784 0.02 1.000 1.00 (0.18–5.46)
Stomach 2 12894 0.02 3 25783 0.01 0.755 1.33 (0.22–7.98)
Thyroid 19 12879 0.15 44 25755 0.17 0.589 0.86 (0.50–1.48)
Breast (females) 101 9922 1.02 178 19786 0.90 0.322 1.13 (0.89–1.45)
Cervix (females) 1 9962 0.01 19 19926 0.10 0.002 0.11 (0.01–0.79)
Ovary (females) 16 9964 0.16 22 19911 0.11 0.261 1.45 (0.76–2.77)
Uterine (females) 7 9962 0.07 22 19923 0.11 0.280 0.64 (0.27–1.49)
Prostate (males) 12 2923 0.41 24 5838 0.41 0.997 1.00 (0.50–2.00)
Testicular (males) 2 2927 0.07 3 5848 0.05 0.756 1.33 (0.22–7.98)
Note: aDue to correction for multiple comparisons (Bonferroni), statistical significance was achieved when P , 0.002.
Abbreviations: CI, confidence interval; IM IFNβ-1a, intramuscular interferon beta-1a; MS, multiple sclerosis.
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cancers, and cervical cancer. No overrepresentation of these 
cancers was observed. Findings from the intramuscular 
IFNβ-1a global safety database analysis were consistent with 
the results from the US claims data analysis. No significant 
differences in malignancy rates were observed between MS 
patients who used intramuscular IFNβ-1a and non-MS popu-
lation controls, MS patients with no intramuscular IFNβ-1a 
use, or untreated MS patients.
We acknowledge the limitations of comparing malig-
nancy reporting rates from the intramuscular IFNβ-1a global 
safety database with malignancy incidence rates. Reporting 
rates derived from spontaneous adverse drug reaction report-
ing in the intramuscular IFNβ-1a global safety database are 
associated with under-reporting. Under-reporting of latent 
events such as malignancy may be further amplified because 
the condition may not emerge until years later, making it less 
likely for the reporter to make an association easily between 
malignancy and any given therapeutic agent. In addition, the 
size of the exposed population can at best be estimated only 
roughly, based on a number of assumptions.
The intramuscular IFNβ-1a-treated population tends 
to consist predominantly of white females between 30 and 
60 years of age (Biogen Idec, data on file). In the postmarket-
ing surveillance evaluation, comparing postmarketing reports 
of malignancies with GLOBOCAN rates is limited by the 
fact that the intramuscular IFNβ-1a reporting rates were not 
standardized to a common age and gender distribution across 
GLOBOCAN regions. In addition, conclusions regarding the 
risk over time are limited due to the fact that the duration of 
intramuscular IFNβ-1a use in MS patients is unknown in this 
analysis. Given these limitations, postmarketing surveillance 
to evaluate changes in the nature of adverse drug reactions over 
time and to monitor for the emergence of unexpected adverse 
drug reactions not captured in trials with short treatment expo-
sure is an essential component of pharmacovigilance.
A subanalysis of the claims data was performed to prevent 
prior immunosuppressive use from potentially confounding 
the calculated risk of developing malignancies. Malignancy 
was compared between subjects in the intramuscular 
IFNβ-1a use group with no history of immunosuppressive 
Table 4 Malignancy in MS patients after IM IFNβ-1a use (n = 12,894) compared with MS patients with no IM IFNβ-1a usea (n = 25,788), 
i3 InVision Data Mart Multiplan
Primary site  
of malignancy
IM IFNβ-1a use IM IFNβ-1a nonusea P valueb Odds ratio  
(95% CI) Malignancy (n) Population (n) % Malignancy (n) Population (n) %
Bladder 11 12892 0.09 27 25775 0.10 0.561 0.81 (0.40–1.64)
Brain 8 12892 0.06 42 25752 0.16 0.006 0.38 (0.18–0.81)
Colorectal 24 12888 0.19 33 25768 0.13 0.168 1.45 (0.86–2.46)
Esophageal 1 12894 0.01 3 25786 0.01 0.717 0.67 (0.07–6.41)
Hodgkin lymphoma 5 12890 0.04 10 25773 0.04 1.000 1.00 (0.34–2.93)
Kidney 8 12890 0.06 25 25779 0.10 0.255 0.64 (0.29–1.42)
Laryngeal 1 12893 0.01 1 25786 0.00 0.627 2.00 (0.13–31.98)
Leukemia 6 12890 0.05 24 25772 0.09 0.105 0.50 (0.20–1.22)
Lip/oral cavity 3 12892 0.02 7 25781 0.03 0.821 0.86 (0.22–3.31)
Liver 3 12894 0.02 5 25787 0.02 0.804 1.20 (0.29–5.02)
Lung 17 12892 0.13 48 25770 0.19 0.209 0.71 (0.41–1.23)
Melanoma 18 12883 0.14 48 25767 0.19 0.288 0.75 (0.44–1.29)
Multiple myeloma 3 12892 0.02 12 25778 0.05 0.252 0.50 (0.14–1.77)
Non-Hodgkin lymphoma 14 12890 0.11 28 25760 0.11 0.998 1.00 (0.53–1.90)
Pancreas 4 12893 0.03 5 25786 0.02 0.489 1.60 (0.43–5.96)
Pharyngeal/ 
nasopharyngeal
2 12893 0.02 7 25786 0.03 0.464 0.57 (0.12–2.75)
Stomach 2 12894 0.02 3 25788 0.01 0.755 1.33 (0.22–7.98)
Thyroid 19 12879 0.15 39 25765 0.15 0.927 0.97 (0.56–1.69)
Breast (females) 101 9922 1.02 174 19650 0.89 0.266 1.15 (0.90–1.47)
Cervix (females) 1 9962 0.01 9 19767 0.05 0.082 0.22 (0.03–1.74)
Ovary (females) 16 9964 0.16 24 19753 0.12 0.392 1.32 (0.70–2.49)
Uterine (females) 7 9962 0.07 17 19763 0.09 0.648 0.82 (0.34–1.97)
Prostate (males) 12 2923 0.41 36 5990 0.60 0.238 0.68 (0.35–1.31)
Testicular (males) 2 2927 0.07 1 6017 0.02 0.230 4.11 (0.37–45.38)
Notes: aIM IFNβ-1a nonuse is defined as no use of IM IFNβ-1a during a patient’s time in the database; bDue to correction for multiple comparisons (Bonferroni), statistical 
significance was achieved when P , 0.002.
Abbreviations: CI, confidence interval; IM IFNβ-1a, intramuscular interferon beta-1a; MS, multiple sclerosis.
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use and subjects in the untreated MS group. Subjects with a 
malignancy in the intramuscular IFNβ-1a use/no immuno-
suppressive use group were excluded if they had at least two 
ICD-9 codes for the malignancy prior to the first intramus-
cular IFNβ-1a prescription date. No increased risk of malig-
nancy was observed in the intramuscular IFNβ-1a use/no 
immunosuppressive use group compared with the untreated 
MS group. Although a subset of malignancies may not have 
been captured, since excluding patients with immunosuppres-
sive use removed cancers treated with immunosuppressive 
drugs from both groups, the comparison of risk between the 
two groups is nevertheless valid.
Though insurance claims data provide observational 
data powered with large numbers, analyses based on these 
data have inherent limitations. To control for potential 
confounders within the claims database analysis, patients 
were matched to population controls for age, gender, and 
follow-up time, and frequency matching based on age was 
performed for the case-to-case comparisons. This evaluation 
did not control for possible cancer risk factors such as diet, 
environmental exposures, family history, smoking status, 
and prior and/or concomitant medication use (except for 
immunosuppressive use). In addition, selection bias may have 
been introduced, as an insurance claims database captures 
only those individuals or family members who carry medical 
insurance. It is difficult to know if and to what extent these 
uncontrolled factors influenced the results, but each group 
analyzed would be similarly biased.
Some patients identified in this analysis as intramuscular 
IFNβ-1a nonusers may have previously used intramus-
cular IFNβ-1a; similarly, patients identified as intramus-
cular IFNβ-1a users may have received other MS therapies 
or immunosuppressive prior to initiating treatment with 
intramuscular IFNβ-1a and prior to entering the database. 
It is not uncommon for an individual to move in and out of 
different insurance plans over time, resulting in treatment 
information for the time before and/or after the individual 
was in an included plan being omitted from the insurance 
claims database. Information would also be missing from 
the database if patients paid out of pocket for pharmacy 
expenses, though few MS patients are likely to do so. As 
a result, it is not possible to eliminate bias or confounding 
Table 5 Malignancy in MS patients after IM IFNβ-1a use (n = 12,894) compared with untreated MS patientsa (n = 12,894), i3 InVision 
Data Mart Multiplan
Primary site  
of malignancy
IM IFNβ-1a use Untreated MSa P valueb Odds ratio  
(95% CI) Malignancy (n) Population (n) % Malignancy (n) Population (n) %
Bladder 11 12,892 0.09 8 12,888 0.06 0.491 1.37 (0.55–3.42)
Brain 8 12,892 0.06 22 12,865 0.17 0.009 0.36 (0.16–0.81)
Colorectal 24 12,888 0.19 22 12,882 0.17 0.769 1.09 (0.61–1.95)
Esophageal 1 12,894 0.01 1 12,893 0.01 1.000 1.00 (0.06–15.99)
Hodgkin lymphoma 5 12,890 0.04 3 12,887 0.02 0.477 1.67 (0.40–6.97)
Kidney 8 12,890 0.06 7 12,887 0.05 0.796 1.14 (0.41–3.15)
Laryngeal 1 12,893 0.01 1 12,893 0.01 1.000 1.00 (0.06–15.99)
Leukemia 6 12,890 0.05 8 12,884 0.06 0.592 0.75 (0.26–2.16)
Lip/oral cavity 3 12,892 0.02 4 12,890 0.03 0.705 0.75 (0.17–3.35)
Liver 3 12,894 0.02 3 12,893 0.02 1.000 1.00 (0.20–4.96)
Lung 17 12,892 0.13 18 12,876 0.14 0.863 0.94 (0.48–1.83)
Melanoma 18 12,883 0.14 21 12,879 0.16 0.630 0.86 (0.46–1.61)
Multiple myeloma 3 12,892 0.02 3 12,882 0.02 0.999 1.00 (0.20–4.95)
Non-Hodgkin lymphoma 14 12,890 0.11 16 12,878 0.12 0.713 0.87 (0.43–1.79)
Pancreas 4 12,893 0.03 2 12,892 0.02 0.410 2.00 (0.37–10.92)
Pharyngeal/ 
nasopharyngeal
2 12,893 0.02 4 12,891 0.03 0.410 0.50 (0.09–2.73)
Stomach 2 12,894 0.02 2 12,891 0.02 1.000 1.00 (0.14–7.10)
Thyroid 19 12,879 0.15 18 12,874 0.14 0.870 1.06 (0.55–2.01)
Breast (females) 101 9922 1.02 87 9884 0.88 0.317 1.16 (0.87–1.54)
Cervix (females) 1 9962 0.01 5 9953 0.05 0.088 0.20 (0.02–0.71)
Ovary (females) 16 9964 0.16 13 9946 0.13 0.580 1.23 (0.59–2.56)
Uterine (females) 7 9962 0.07 12 9951 0.12 0.247 0.58 (0.23–1.48)
Prostate (males) 12 2923 0.41 17 2926 0.58 0.352 0.71 (0.34–1.48)
Testicular (males) 2 2927 0.07 0 2939 n/a n/a n/a
Notes: aUntreated MS defined as no use of an indicated MS treatment and no immunosuppressive treatment at any time in the database; bDue to correction for multiple 
comparisons (Bonferroni), statistical significance was achieved at P , 0.002.
Abbreviations: CI, confidence interval; IM IFNβ-1a, intramuscular interferon beta-1a; MS, multiple sclerosis; n/a, not applicable.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
319
IM IFNβ-1a malignancy riskTherapeutics and Clinical Risk Management 2012:8
within a retrospective claims data analysis fully, a limitation 
that is not differentiated by treatment group.
Like any electronic medical database, this database may 
have included coding inaccuracies. However, the capture of 
inaccurate data was limited by the requirement of at least 
two diagnosis codes for each malignancy. In addition, any 
inaccuracies resulting from coding errors should be equally 
represented between the intramuscular IFNβ-1a use group 
and each comparison group. Finally, considering that cancers 
may take years to develop, we acknowledge that the short 
follow-up time of 3 years restricts the conclusions that can 
be drawn from this analysis.
Despite the limitations of an insurance claims dataset, it 
provides the strength of a large reference population with a 
known denominator and permits the evaluation of various 
treatment exposures in cohorts of patients with MS as well 
as a non-MS control population. In addition, the longitudi-
nal nature of a claims database captures continuous service 
dates rather than the individual assessments traditionally 
performed in cohort studies, allowing for an evaluation of 
the timing of events.21
This study assessed the risk of malignancy in patients 
using intramuscular IFNβ-1a for the treatment of MS. 
  Evaluating two data sources, postmarketing surveillance, and 
US claims data, we found no evidence of an increased risk 
of cancer with the use of intramuscular IFNβ-1a.
With intramuscular IFNβ-1a, as with all drugs, the risks 
and benefits of the therapy must be considered when select-
ing treatments for individual patients. The complexity of 
making appropriate treatment decisions in MS increases 
as more options for treatment, each with a unique safety 
profile, become available. For many of the newer therapies, 
long-term safety has yet to be determined. This evaluation 
provides valuable information about the risk of malignancy 
with intramuscular IFNβ-1a based on 15 years of real-world 
experience and supports the safety profile previously estab-
lished through the intramuscular IFNβ-1a development 
program and pivotal trials.
Disclosure
Anne Dilley of Biogen Idec Inc assisted with the method-
ology development, and Susan Friend of Biogen Idec Inc 
assisted in compiling the intramuscular IFNβ-1a safety data 
used in this paper.
GB, BS, KC, and MW are all employees and stockhold-
ers of Biogen Idec Inc. This work was supported by Biogen 
Idec Inc.
References
  1.  Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372: 
1502–1517.
  2.  Kingwell E, Tremlett H. Interferons and multiple sclerosis: is it plau-
sible that beta-IFN treatment could influence the risk of cancer among 
MS patients? Expert Rev Neurother. 2009;9:1263–1265.
  3.  Ottenhoff  TH. Selective modulation of  T-cell responses in autoimmunity 
and cancer. Immunol Today. 1996;17:54–55.
  4.  Achiron A, Barak Y, Gail M, et al. Cancer incidence in multiple sclerosis 
and effects of immunomodulatory treatments. Breast Cancer Res Treat. 
2005;89:265–270.
  5.  Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer 
risk among patients with multiple sclerosis and their parents. Neurology. 
2009;72:1170–1177.
  6.  Palo J, Duchesne J, Wikstrom J. Malignant diseases among patients 
with multiple sclerosis. J Neurol. 1977;216:217–222.
  7.  Møller H, Kneller RW, Boice JD Jr, Olsen JH. Cancer incidence fol-
lowing hospitalization for multiple sclerosis in Denmark. Acta Neurol 
Scand. 1991;84:214–220.
  8.  Midgard R, Glattre E, Grønning M, Riise T, Edland A, Nyland H. 
Multiple sclerosis and cancer in Norway: a retrospective cohort study. 
Acta Neurol Scand. 1996;93:411–415.
  9.  Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year 
follow-up. Mult Scler. 1999;5:293–296.
  10.  Sumelahti ML, Pukkala E, Hakama M. Cancer incidence in multiple 
  sclerosis: a 35-year follow-up. Neuroepidemiology. 2004;23:224–227.
  11.  Nielsen NM, Rostgaard K, Rasmussen S, et al. Cancer risk among 
patients with multiple sclerosis: a population-based register study.   
Int J Cancer. 2006;118:979–984.
  12.  Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in 
patients with motor neuron disease, multiple sclerosis and Parkinson’s 
disease: record linkage studies. J Neurol Neurosurg Psychiatry. 
2010;81:215–221.
  13.  Handel AE, Ramagopalan SV . Multiple sclerosis and risk of cancer:   
a meta-analysis. J Neurol Neurosurg Psychiatry. 2010;81:1413–1414.
  14.  Lebrun C, Debouverie M, Vermersch P, et al. Cancer risk and impact 
of disease-modifying treatments in patients with multiple sclerosis. 
Mult Scler. 2008;14:399–405.
  15.  Sandberg-Wollheim M, Kornmann G, Bischof D, et al. The risk 
of malignancy is not increased in patients with multiple sclerosis 
treated with subcutaneous interferon beta-1a: analysis of data from 
clinical trial and post-marketing surveillance settings. Mult Scler. 
2011;17:431–440.
  16.  Lebrun C, Vermersch P, Brassat D, et al. Cancer and multiple scle-
rosis in the era of disease-modifying treatments. J Neurol. 2011; 
258:1304–1311.
  17.  Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular inter-
feron beta-1a for disease progression in relapsing multiple sclerosis. 
The Multiple Sclerosis Collaborative Research Group (MSCRG).   
Ann Neurol. 1996;39:285–294.
  18.  Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon 
beta-1a therapy initiated during a first demyelinating event in mul-
tiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343: 
898–904.
  19.  Maintenance and Support Services Organization. Medical Dic-
tionary for Regulatory Activities (MedDRA). Available from: 
http://www.meddramsso.com. Accessed April 24, 2012.
  20.  Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 
  GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: 
IARC CancerBase no 10. Lyon, France: International Agency for 
Research on Cancer; 2010. Available from: http://globocan.iarc.fr. 
Accessed November 8, 2011.
  21.  Stürmer T, Funk MJ, Poole C, Brookhart MA. Nonexperimental 
comparative effectiveness research using linked healthcare databases. 
Epidemiology. 2011;22:298–301.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
320
Bloomgren et alTherapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Therapeutics and Clinical Risk Management 2012:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
321
IM IFNβ-1a malignancy risk